Shionogi Of Japan Expects Peramivir Approval In January For Flu
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi expects to begin selling peramivir, an intravenous flu drug, in Japan as early as January, when the company hopes to receive health ministry approval
You may also be interested in...
Lupin Optimistic On Albuterol Given COVID-19 Demand
Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.
ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
QUOTED. 2 June 2020. Pamela Spence.
Medtech insiders offer 10 strategies for medtech companies to rethink their businesses. See what Ernst & Young’s global health sciences and wellness leader Pamela Spence said about it here.
Need a specific report? 1000+ reports available
Buy Reports